| 摘要 |
<p>The invention provides a method of determining type III collagen degradation, comprising quantitating in a body fluid, optionally urine, blood, serum or synovial fluid, the concentration of at least a first 3-hydroxypyridinium cross-linked type III collagen telopeptide.</p> |
